Pharma Stability: Insights, Guidelines, and Expertise
Miscommunication about shelf life and expiry can lead to incorrect labeling, misinformed decisions during regulatory submissions, poor stock rotation, and compliance issues during audits. Regulatory authorities like the USFDA and EMA expect alignment between technical documentation and packaging claims. Therefore, pharma professionals must ensure stakeholders understand these terms clearly.
Click to read the full article.
Labeling errors involving shelf life and expiry are among the most frequently cited issues during GMP audits. The consequences range from market withdrawal to patient risk. A robust internal checklist helps mitigate such risks by offering a standardized approach for cross-departmental teams.
Click to read the full article.
Despite stringent regulatory compliance norms and training efforts, confusion between shelf life and expiry arises due to overlapping definitions, inconsistent communication, and inadequate function-specific training. These misconceptions are particularly dangerous during labeling, stability data interpretation, and audit responses.
Click to read the full article.
Incorrect interpretation of shelf life and expiry can result in:
Click to read the full article.
Expiry dates are initially set based on the shelf life derived from real-time and accelerated stability studies. However, over time, more long-term data becomes available, and companies may seek to extend the expiry for:
Click to read the full article.
Incorrect interpretation of expiry vs shelf life has led to:
Click to read the full article.
Updating expiry dates improves product lifecycle value and reduces waste, but it must be handled with scientific rigor and procedural discipline to remain compliant with regulators like the USFDA, EMA, and CDSCO.
Click to read the full article.
Complaints about expired or near-expiry drugs in the market are treated seriously by agencies like the USFDA and EMA. If handled incorrectly, they may trigger:
Click to read the full article.
Authorities like EMA, CDSCO, and USFDA expect clear and consistent usage of “retest” and “expiry” terms in registration dossiers, COAs, and GMP documentation. Mislabeling or incorrect document trails can lead to:
Click to read the full article.
The incident occurred at a mid-sized generic drug manufacturer supplying solid oral dosage forms to the US and European markets. The product in question was an antihypertensive tablet with an approved shelf life of 24 months.
Click to read the full article.